Member Info for equitrder

Amryt

Maybe you can ask CF how many share our Chairman has bought? and how many hours he is stamping on his card at Amyst.

and a couple of days ago certain people were saying that .175 is a great entry point. Oh its a 20 folder u can't lose. Yeah right

You do realise 50k is only £8000. Amazing!!!! We need 500 thousand shares block trades to move this stock. Has our Chairman bought any yet???

With the ask coming in and low volume I'd imagine its going lower. More power to our elite management term. We will be down 50% from the reorganisation very soon.

God man u need to take a chill pill,this is no conspiracy! I made a comment that rally was short lived and now the stock could be heading down to test its 52 week low probably on very low volume.Then the weak hands sell you have capitulation and the stock puts in a bottom.

You said 'someone has left their finger on the buy button' And I said 'What planet are u on???? 200,000 shares is a measly £34,000' If my memory serves me right. Not sure what point your trying to make.

Speaking of 'tax loss selling' its getting close to that time of the year. I'm not going to be selling but I won't be adding until I see a large purchase by our cash rich chairman or we have capitulation in the share price on good volume. In the mean time I will view my thoughts freely here on this forum!!

Wasn't much momentum in that rally! I'd imagine now we will test the 52 week low. I would be a bit worried sometimes they bring these Aim listed companies down to cash value.

Sarcasm my dear fellow...

So maybe all the serious buying was Earlybird and ShrewD doing their dummy trades (:

This is the part I was talking about.I hadn't seen the full report until tonight.They even said that they are not sure how Episalvan works. 'The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Episalvan’s benefits are greater than its risks and recommended that it be approved for use in the EU.'

Never said there wasn't 'potential' potentially. Your way off on your estimates to get Episalvan to market. Excerpts from the European approval.. The last part is not exactly a ringing endorsement! What benefits of Episalvan have been shown in studies? Episalvan was studied in two main studies involving 217 patients with partial-thickness skin wounds in patients who underwent skin graft surgery. The patients received Episalvan together with wound dressing on one half of the wound, while the other half of the wound was treated with standard wound dressing only. In the first study, the average time from surgery to wound closure was 17.1 days for the wounds treated with standard wound dressing only and 15.5 days for the wounds also treated with Episalvan. The respective times were 16.0 and 15.1 days respectively in the second study. A third study involved 57 patients with partial-thickness burn wounds who had half their wound treated with Episalvan and the other half with a standard disinfectant gel. Both wound halves were also covered with a wound dressing. The average time to wound closure was 8.8 days for the wounds treated with standard disinfectant gel and 7.6 days for the wounds treated with Episalvan. What are the risks associated with Episalvan? The most common side effects with Episalvan are wound complications, pain in the skin (both of which may affect more than 3 in 100 people) and pruritus (itching) (which may affect more 1 in 100 people). For the full list of all side effects and restrictions reported with Episalvan, see the package leaflet. Why is Episalvan approved? Episalvan gel was shown to reduce wound healing times. Although the differences were small they were considered relevant for patients with partial-thickness wounds, which can be difficult to heal and for which treatment options are limited. With regard to safety, no major issues were identified and side effects were manageable. The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Episalvan’s benefits are greater than its risks and recommended that it be approved for use in the EU.

Lol dummy trades... I heard it all now

There is no justification for your ridiculous valuation over the medium term. There are 100's of small pharmaceutical companies out there with real revenues that dont even come close to that valuation. That said I still see potential here.

Now that pumping!!!!!

Thinice 40 grand in trades and we get 'someone has left their finger on the buy button' and then 'Perfect entry timing' If that's not pumping I don't know what is. Yeah I see its .17 bid now

I don't like false info.. If a person was to sell the bid is only .165 Hense FLAT

Ahh the pumpers are back

What planet are u on???? 200,000 shares is a measly £34,000... and most were sells around the .165 level